A U.S. FDA advisory panel voted to include BPC-157 on the 503A Bulks List, paving the way for compounded peptide treatments and sparking an approximately 10% jump in Hims & Hers Health’s stock on July 23, 2026. This regulatory development could broaden Hims & Hers’ telehealth offerings into the growing peptide market, which is viewed by analysts as a multibillion-dollar opportunity. The company sits around an $8.1 billion market cap with over 2 million subscribers, underscoring its significant scale in the telehealth and pharmaceutical space. Insider activity shows about $3.9 million in shares sold over the past three months, signaling potential near-term concerns despite the positive regulatory news. Analysts note mixed technical signals and near-term volatility, but the favorable panel recommendation could extend access to peptide therapies and support a longer-term bullish outlook. The FDA’s recommendation is advisory, and final policy will depend on the agency’s ruling, even as Hims & Hers has pursued related capacity expansion to support peptide therapies.